Safety
-
Orfadin (nitisinone) capsules
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2013
ADVERSE REACTIONS
- High Plasma Tyrosine Levels
-
-







